We are thrilled to announce our participation in the upcoming AD/PD 2025 Congress in Vienna (April 1-5) // Join us at AD/PD2025 Congress in Vienna (April 1-5)
This hybrid event will unite experts and leaders from the health, neuroscience, and biotechnology sectors to discuss the latest advancements in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as in their diagnosis and treatment.
What will we present?
- Oral Presentation: We will present our groundbreaking research on the ABvac40 vaccine and its impact on cerebral amyloid angiopathy (CAA). Our presentation, titled “Impact of ABvac40, an anti-Aβ40 vaccine, on CAA pathology: a comprehensive re-evaluation of MRI findings from the AB1601 phase 2 study” will showcase key findings from our in-depth analysis of MRI data. Our results suggest that ABvac40 may significantly reduce the incidence of new cerebral microbleeds and protect against CAA progression over a 24-month period in this clinical trial. These findings highlight the therapeutic potential of ABvac40 for CAA and Alzheimer’s patients, while also suggesting its potential role in reducing the ARIA risk associated with passive immunotherapies.
Catch our talk on April 5
- On-demand (Virtual) Oral Presentation + Onsite Poster: We will also present our findings on the diagnostic performance of ABtest-MS a blood-based antibody-free HPLC-MS/MS method to identify patiens with amyloid deposition, in mild cognitive impairment (MCI) patients, with the presentation: “Diagnostic Performance of ABtest-MS in mild cognitive impairment: findings from the clinical validation study”. In addition, our onsite poster will be available on April 2nd and 3rd (Shift 1), where we will provide further insights into the ability of ABtest-MS to identify amyloid deposition in two real-world cohorts, highlitghting its potential to reduce the number of PET scans o lumbar punctures in clinical practice.
This is a pivotal moment to share our latest advancements in the diagnosis and treatment of Alzheimer’s. We are eager to connect with professionals in the field, exchange insights, and contribute our perspective on these critical issues.
Meet our team in Vienna:
- José Antonio Allué – Mass Spectrometry Manager
- María Pascual Lucas – Senior Researcher, Scientific Affairs
We look forward to seeing you in Vienna or joining us virtually!
#ADPD2025 #Neuroscience #Alzheimer #Research #ABvac40 #ABtestMS #Araclon
